In Brief This Week: Bio-Rad; Fitch, Abbott; Gentris; Indiana Biosciences Research Institute; Strand Life Sciences; Oncospire Genomics | GenomeWeb

NEW YORK (GenomeWeb News) – Bio-Rad Laboratories said in its recently filed Form 10-Q that it identified errors in financial statements starting in 2008 through the second quarter of 2013 related to the valuation of finished goods inventory in the company's Life Science segment. It expensed inventory in amounts greater than actual costs for non-sales transactions. To correct for the errors, it has increased net income in full-year 2008 by $600,000; in 2009 by $800,000; in 2010 by $700,000; in 2011 by $800,000; and in 2012 by $1.3 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.